However, in late-stage prostate cancer and following androgen deprivation therapy, cancer cells adapt to low AR–androgen complex signaling and activate alternative signaling cascades leading to survival, proliferation, and metastasis [3]. This evidence concerns the gene AR and prostate carcinoma.